Iwabradyna – „piękny” lek w leczeniu pacjentów z chorobą wieńcową i dysfunkcją lewej komory? Badanie BEAUTIFUL Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2009
Słowa kluczowe:
iwabradyna, choroba wieńcowa, dysfunkcja lewej komory
##plugins.themes.bootstrap3.article.main##
Abstrakt
Badanie BEAUTIFUL zostało zaprojektowane, aby ocenić, czy dodanie iwabradyny do standardowej terapii zmniejsza śmiertelność i chorobowość z przyczyn sercowo-naczyniowych u chorych ze stabilną chorobą wieńcową i dysfunkcją lewej komory. U pacjentów ze spoczynkową akcją komór w momencie randomizacji ≥70 uderzeń na minutę stosowanie iwabradyny wiązało się z redukcją częstości hospitalizacji z powodu zawału serca lub niestabilnej dławicy i rewaskularyzacji wieńcowych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Trzeciak, P. (2009). Iwabradyna – „piękny” lek w leczeniu pacjentów z chorobą wieńcową i dysfunkcją lewej komory? Badanie BEAUTIFUL. Medycyna Faktów , 2(1(2), 17-23. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2677
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Kannel W.B., Kannel C., Paffenbarger R.E. Jr., Cupples L.A.: Heart rate and cardiovascular mortality: the Framingham Study. Am. Heart J. 1987; 113: 1489-1494.
2. Palatini P., Julius S.: Elevated heart rate: a major risk factor for cardiovascular disease. Clin. Exp. Hypertens. 2004; 26: 637-644.
3. Diaz A., Bourassa M.G., Guertin M.C., Tardiff J.C.: Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J. 2005; 26: 967-974.
4. Kolloch R., Legler U.F., Champion A. et al.: impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International VErapamil-SR/trondalapril Study (INVEST). Eur. Heart J. 2008; 29: 1327-1334.
5. Kasprzak J.D., Tymiński M.: Iwabradyna w badaniu Beautiful – implikacje dla klinicysty. Kardiologia po Dyplomie 2008, wrzesień; wydanie specjalne: 3-7.
6. Przybysz B., Serafin A., Filipiak K.J.: Iwabradyna – alternatywa czy „wartość dodana” w stosunku do leków β-adrenolitycznych? Choroby Serca i Naczyń 2007; 4: 169-176.
7. Joannides R., Moore N., Iacob M.: Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br. J. Clin. Pharmacol. 2006; 61: 127-137.
8. Manz M., Reuter M., Lauck G., Omran H., Jung W.: A single intravenous dose of ivabradine, a novel I (f ) inhibitor, lowers heart rate but dose not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003; 100: 149-155.
9. Camm A.J., Lau C.P.: Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R. D. 2003; 4: 83-89.
10. Fox K., Garcia M.A., Ardissino D., Buszmen P., Camici P.G., Crea F., Daly C., De Backer G., Hjemdahl P., Lopes-Sendon J., Marco J., Morais J., Pepper J., Sechtem U., Simoons M., Thygesen K.: Task force on the management of stable angina pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG): Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur. Heart J. 2006; 27: 1341-1381.
11. Graham I., Atar D., Borch-Johnsen K.: European guidlines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 2007; 28: 2375-2414.
12. Fox K., Ferrari R., Tendera M., Steg P.G., Ford I.: Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I (f ) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am. Heart J. 2006; 152: 860-866.
13. The BEAUTIFUL Study Group: The BEAUTIFUL Study: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction – baseline characteristics of the study population. Cardiology 2008; 110: 271-282.
14. MorBidity-mortality EvAlUaTion of the I (f ) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction: Breaking new ground in coronary artery disease. 2008 Servier, edited by Fox K, Ferrari R on behalf of the BEAUTIFUL Executive Committee.
15. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. (on behalf of the Beautiful Investigators): Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial [online: www.thelancet.com, published August 31, 2008].
2. Palatini P., Julius S.: Elevated heart rate: a major risk factor for cardiovascular disease. Clin. Exp. Hypertens. 2004; 26: 637-644.
3. Diaz A., Bourassa M.G., Guertin M.C., Tardiff J.C.: Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J. 2005; 26: 967-974.
4. Kolloch R., Legler U.F., Champion A. et al.: impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International VErapamil-SR/trondalapril Study (INVEST). Eur. Heart J. 2008; 29: 1327-1334.
5. Kasprzak J.D., Tymiński M.: Iwabradyna w badaniu Beautiful – implikacje dla klinicysty. Kardiologia po Dyplomie 2008, wrzesień; wydanie specjalne: 3-7.
6. Przybysz B., Serafin A., Filipiak K.J.: Iwabradyna – alternatywa czy „wartość dodana” w stosunku do leków β-adrenolitycznych? Choroby Serca i Naczyń 2007; 4: 169-176.
7. Joannides R., Moore N., Iacob M.: Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br. J. Clin. Pharmacol. 2006; 61: 127-137.
8. Manz M., Reuter M., Lauck G., Omran H., Jung W.: A single intravenous dose of ivabradine, a novel I (f ) inhibitor, lowers heart rate but dose not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003; 100: 149-155.
9. Camm A.J., Lau C.P.: Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R. D. 2003; 4: 83-89.
10. Fox K., Garcia M.A., Ardissino D., Buszmen P., Camici P.G., Crea F., Daly C., De Backer G., Hjemdahl P., Lopes-Sendon J., Marco J., Morais J., Pepper J., Sechtem U., Simoons M., Thygesen K.: Task force on the management of stable angina pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG): Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur. Heart J. 2006; 27: 1341-1381.
11. Graham I., Atar D., Borch-Johnsen K.: European guidlines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 2007; 28: 2375-2414.
12. Fox K., Ferrari R., Tendera M., Steg P.G., Ford I.: Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I (f ) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am. Heart J. 2006; 152: 860-866.
13. The BEAUTIFUL Study Group: The BEAUTIFUL Study: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction – baseline characteristics of the study population. Cardiology 2008; 110: 271-282.
14. MorBidity-mortality EvAlUaTion of the I (f ) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction: Breaking new ground in coronary artery disease. 2008 Servier, edited by Fox K, Ferrari R on behalf of the BEAUTIFUL Executive Committee.
15. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. (on behalf of the Beautiful Investigators): Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial [online: www.thelancet.com, published August 31, 2008].